Open an account

IM Cannabis

IMCC · CANADIAN

$1.40−$0.10 (−6.67%)TodayMarket closed ·
Prev close $1.50

About IMCC

IM Cannabis Corp. engages in the production and sale of medical cannabis products. The firm's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The firm also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The firm's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.

Employees
44
Headquarters
TORONTO, Central(HaMerkaz)
Listed
Nov 5, 2019
Sector
Health Care
Industry
Pharmaceuticals
Website
imcannabis.com

IMCC key statistics

Market cap
1.01M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.25M
Volume
57.80K
Open price
$1.47
High today
$1.48
Low today
$1.37
52 Week high
$3.16
52 Week low
$0.475

IM Cannabis (IMCC) at a glance

As of Oct 20, 2026, IM Cannabis (IMCC) shares are priced at $1.40, giving the company a market cap of 1.01M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.37 and $1.48. The current price is 2.2% above the day's low and 5.4% below its high.

Volume so far is 57.80K shares, below the average of 3.25M shares a day.

Over the past year IM Cannabis has ranged from $0.475 to $3.16, and now sits 34% of the way up that range.

IM Cannabis met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY26 it reported -$0.3837 per share against an estimate of $0.00.

IMCC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 66.0% on average.

  1. Q4 FY23: reported -$1.50 per share against an estimate of -$1.03
  2. Q1 FY24: reported -$2.52 per share against an estimate of -$1.22
  3. Q2 FY24: reported -$0.23 per share against an estimate of -$1.20
  4. Q3 FY24: reported -$0.41 per share against an estimate of -$1.44
  5. Q4 FY24: reported -$0.22 per share against an estimate of -$0.5508
  6. Q2 FY25: reported -$0.0964 per share against an estimate of -$0.1999
  7. Q4 FY25: reported -$1.20 per share against an estimate of $0.1255
  8. Q1 FY26: reported -$0.3837 per share against an estimate of $0.00

IMCC news

  • Press releasePRNewswire

    IM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance Sheet

  • Press releasePRNewswire

    IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares

  • Press releasePRNewswire

    IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Avi Kapoor

    Crude Oil Gains 1%; Cintas Earnings Top Views

  • Akanksha Bakshi

    IM Cannabis Stock Falls after $1.31 Million Offering Follows Drone Deal

  • Avi Kapoor

    Dow Falls 100 Points; General Mills Posts Upbeat Q1 Earnings

  • Press releasePRNewswire

    IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares

  • Press releasePRNewswire

    IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market

Similar companies

Companies in the same industry as IM Cannabis

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.